Akero Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
-12.87 | -274.25 | -95.31% | -6.85 | +87.83% |
| P/S |
|
0 | 56.99 | -100% |
|
|
| P/BV |
|
2.49 | 256.7 | -99.03% |
|
|
| P/FCF |
|
-14.1 | -196.64 | -92.83% |
|
|
| Ev/Ebitda |
|
-5.48 | 12.51 | -143.8% |
|
|
| Ev/S |
|
0 | 468.02 | -100% |
|
|
| Ev/FCF |
|
-6.8 | -237.28 | -97.14% |
|
|
| E/P |
|
-0.0777 | 0.0224 | -447.43% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | -341.3 | -100% | 0 | 0% |
| ROE |
|
-39.22 | 103.63 | -137.84% |
|
|
| ROA |
|
-35.85 | -2.84 | 1163.22% |
|
|
| ROIC |
|
0 | 1.17 | -100% |
|
|
| ROS |
|
0 | -298.77 | -100% |
|
|
| ROCE |
|
-34.23 | 3.3 | -1137.35% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.1277 | 0.9675 | -113.2% | -0.109 | +17.21% |
| Nеt Debt/Ebitda |
|
1.06 | 1.05 | 1.45% |
|
|
| Debt/Ratio |
|
0.0441 | 0.179 | -75.34% |
|
|
| Debt/Equity |
|
0.101 | 1.58 | -93.63% |
|
|
| Debt/Net Income |
|
-0.1446 | -1.51 | -90.42% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5339 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.8444 | -100% | ||
| DSI |
|
0 | 0.2147 | -100% |
|
|
| Average dividend growth |
|
0 | 1.27 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.5087 | -100% |
|
|
| Average percentage for payments |
|
0 | 59.63 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5339 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | -90.69 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
256.17 | -111.17 | -330.43% | ||
| Growth impulse Net Income in 5 years |
|
218.23 | -103.34 | -311.18% | ||
| Growth impulse FCF in 5 years |
|
224.31 | -114.74 | -295.49% | ||
| Growth impulse EPS in 5 years |
|
49.14 | -98.04 | -150.12% |
IP Score
3.94/10
